Li Jianwei's Form 4 filing
Estrella Immunopharma, Inc. (ESLA) · filed Mar 17, 2022
- Accession no.
- 0001104659-22-035068
- Filed
- Mar 17, 2022
- Trade date
- Mar 4, 2022
- Filing delay
- 13 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 0 derivative transactions. It was filed 13 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Li JianweiCIK 0001858469 | Director, Officer (Co-Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 4, 2022 | Common Stock | PPurchaseAcquired | +141,970 | $314,700.00 | +$44,677,959,000 | 1,253,730 | Direct | Price outlier |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.